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Editorial: ulcerative colitis submucosal fibrosis and
inflammation: more than just strictures
Intestinal fibrosis is associated with chronic intestinal inflammation
in IBD, generally reflecting long-lasting illness, where persistent tis-
sue damage and healing result in scar tissue formation.1 It has been
stated that inflammation is required for the initiation of fibrosis, as
both share the same distribution.2 However, inflammation seems to
play a minor role in fibrosis progression.3 Transmural inflammation
and fibrosis are common features of stricturing Crohn’s disease
(CD),1 however, in ulcerative colitis (UC), both inflammation and
extracellular matrix (ECM) deposition are generally restricted to the
colonic mucosal and submucosal layers,4,5 affecting deeper layers
only after profound ulcers below to submucosa.5 Fibrosis in UC is
characterised by marked thickening of muscularis mucosae6,7 and
excessive ECM deposition in the submucosa,8 seldom leading to
strictures.7 In UC, fibrosis has been related with ulcers and longer
disease duration—the latter linked to higher risk of malignancy.5 UC
is now seen as a potentially progressive disease where fibrosis may
lead to diffuse increased wall stiffness, resulting in motility abnor-
malities, anorectal dysfunction, rectal urgency and incontinence.5
In a recent issue of AP&T, Gordon and colleagues depicted the
first comprehensive assessment of fibrosis in UC.9 They studied 706
H&E and Masson Trichrome stained sections of 89 UC total colec-
tomy or proctocolectomy specimens, which were compared to those
of Crohn’s colitis, diverticular disease and normal colons. Inflamma-
tion was graded according to Geboes score and fibrosis over a new
UC submucosal fibrosis score (grading 0 to 4) for each segment, with
the average designated as “fibrosis burden score.” They further cor-
related the section studies results with histological findings on muco-
sal biopsies taken <4 weeks prior to surgery matched for colon
location, with no endoscopic biopsy features predicting the degree
of submucosal fibrosis.
The systematic approach used allowed the identification of clini-
cal and pathological associations supporting the concept of inflam-
mation-driven fibrogenesis in UC: submucosal fibrosis and muscularis
mucosae thickening were restricted to involved segments of the
colon, showing a gradient from proximal to distal colon; refractory
disease was associated with higher degrees of fibrosis and muscu-
laris mucosae thickening; and the degree, severity and histological
aspects of active inflammation and chronic mucosal injury correlated
with the grade of fibrosis. Importantly, the amount of fibrosis was
not associated with disease duration but with severity of inflamma-
tion, which contrasts with previous studies. Likewise, no relation was
found between the degree of fibrosis or average muscularis mucosae
thickening and the length of the colon specimen, which contradicts
the traditional view that submucosal fibrosis is responsible for the so
called “lead pipe colon.”
In summary, this paper comprehensively demonstrates that UC is a
progressive disease characterised by submucosal fibrosis and muscu-
laris mucosae thickening associated with both severity and chronicity
of inflammation. We now have evidence to support that inflammation
in UC drives not only an increased risk of colorectal neoplasia,10 but
also of intestinal fibrosis, reinforcing the importance of deep remission
(including histological remission) as a therapeutic target in UC.
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Editorial: older-onset inflammatory bowel disease—is it time
to start looking beyond a number?
In 2003, the Montreal Working Group expanded on the Vienna sub-
classification of inflammatory bowel disease (IBD) to distinguish adult
from paediatric-onset disease.1 Now an increasingly complex inter-
play between biology, prognosis, and therapy response has led to
further stratification of Crohn’s disease (CD) and ulcerative colitis
(UC) in adults according to age of disease onset.
The number of older IBD patients is growing with nearly a quar-
ter of IBD diagnoses made in patients ≥60 years old.2,3 Concurrently,
studies have identified clinical distinctions between older and adult-
onset IBD.2,4,5 Ma~nosa et al, in one of the largest retrospective mul-
ticenter studies examining older-onset IBD, found that compared to
adult-onset disease, older patients have a less aggressive disease
phenotype, but similar progression of disease.6 A previous multicen-
ter study has shown a decreased risk of disease progression in
older-onset disease,4 but this finding has not been consistent.5
Ma~nosa et al showed less use of immune suppression and anti-TNF
agents in elderly and similar rates of TNF-related complications
between older-onset and adult-onset cases. They also found that
older-onset UC patients were more likely to undergo surgery with
similar post-operative complications between older-onset and adult-
onset IBD patients. The authors conclude that in light of their find-
ings in older-onset IBD, surgical management should be considered
“as a real alternative” in UC and that therapeutic decisions in CD be
similar to those with adult-onset disease.6 However, in a population-
based analysis, thiopurine use decreased the risk of surgery in older-
onset UC.7 In developing optimal treatment algorithms in older-onset
IBD, the risk of surgical and medical complications needs to be
determined by prospective studies examining appropriate therapeutic
endpoints and drug efficacy. More definitive therapeutic strategies in
older-onset IBD will be difficult to develop until then.
Even as recent data sheds further light on disease and therapy-
related complications in older-onset IBD, the results fail to explain
the worse disease outcomes in a less aggressive IBD phenotype in
the elderly.2,5,6 Future studies accounting for disease activity in
1034 | INVITED EDITORIALS
© 2018 John Wiley & Sons Ltd
